Nasdaq notifies Charming Medical of anticipated delisting (MCTA:NASDAQ)
Nasdaq notified Charming Medical (MCTA) of anticipated delisting by November 9, 2026, unless the company appeals. The decision follows standard exchange procedures.
How this was made
The 30-second read
Why it matters
The delisting notice signals a significant compliance breach, likely prompting a sell‑off and reduced market access.
Market read
Primary corporate action affecting MCTA's listing status and liquidity.
What to watch
Potential for a reverse split or private placement to regain compliance, which could stabilize the share price.
Background
Charming Medical (MCTA) is a Nasdaq‑listed biotech facing compliance issues.
Ticker impact
Nasdaq notified Charming Medical of delisting effective Nov 9, 2026 unless appealed.
likely downward pressure as investors assess delisting risk
Delisting notices are material corporate actions that typically trigger sell‑offs, especially for small‑cap stocks.
Market effects
May affect other small‑cap biotech listings and raise scrutiny on Nasdaq compliance.
Limited to U.S. market participants holding MCTA.
Minimal global impact.
Counterpoint
If the company successfully appeals, the delisting risk could be mitigated, offering a short‑term buying opportunity on a dip.
Key entities
- ExchangeNasdaq Stock Market
Issuer of the delisting notice.
- CompanyCharming Medical
Subject of the delisting notice.




